WHITEHOUSE STATION, N.J.--Merck, known as MSD outside the United States and Canada, today said a jury found in its favor in the Glynn v. Merck case in the U.S. District Court for the District of New ...

WHITEHOUSE STATION, N.J., Oct. 4, 2010 - Merck & Co., Inc. today said it will appeal a decision by the U.S. District Court for the Southern District of New York that reduced the jury verdict from $8 ...

Women who have ever used alendronate sodium may be at an increased risk of incident atrial fibrillation, according to recent data published in the Archives of Internal Medicine. Researchers from ...

In re Fosamax (Alendronate Sodium), No. 11-5304, 08-08; U.S. District Court (DNJ); opinion by Pisano, U.S.D.J.; filed June 27, 2013. DDS No. 36-7-xxxx [17 pp.] Fosamax (Alendronate Sodium) is approved ...

Alendronate sodium is a bisphosphonate used to treat Paget disease of bone (PDB). The approved dosage of 40 mg/day for 6 months is generally well tolerated, but esophageal irritation can occur if the ...

Sun Pharma announced a recall of Alendronate Sodium Tablets 70mg, the generic version of Fosamax. Sun Pharma announced a recall of Alendronate Sodium Tablets 70mg, the generic version of Merck‘s ...

TRENTON, N.J. — At least three generic versions of the popular osteoporosis treatment Fosamax are headed for pharmacy shelves with the expiration of the drug’s main patent Wednesday, bringing patients ...

Merck put Fosamax (alendronate sodium) and its $3 billion in total 2007 sales inits rear-view mirror yesterday, following the lapse of patent protection on theosteoporosis drug. Merck forecast that ...

(Reuters) - A federal appeals court on Wednesday revived claims by several hundred plaintiffs who accused Merck & Co of failing to adequately warn about the risks of thigh bone fractures associated ...

BINOSTO (alendronate sodium) 70mg effervescent tablet for oral solution by Mission Pharmacal EffRx announced that the FDA has approved Binosto (alendronate sodium) Effervescent Tablets for the ...